How should I transition from lurasidone (Latuda) 40 mg to quetiapine (Seroquel)?

How to Switch from Latuda 40 mg to Seroquel

Use a gradual cross-titration approach over 1-2 weeks, starting Seroquel at 50 mg/day while slowly tapering Latuda, to minimize the risk of psychotic relapse and withdrawal symptoms while accounting for the different receptor profiles of these medications.

Switching Strategy

The most appropriate method is gradual cross-titration rather than abrupt switching. While the FDA label notes that immediate discontinuation may be acceptable for some patients, individualized gradual switching minimizes risks in clinical practice 1. The 2025 INTEGRATE guidelines emphasize that antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication 2.

Recommended Cross-Titration Schedule

Week 1:

• Day 1-2: Start Seroquel 50 mg at bedtime, continue Latuda 40 mg
• Day 3-4: Increase Seroquel to 100 mg, reduce Latuda to 20 mg
• Day 5-7: Increase Seroquel to 200 mg, discontinue Latuda

Week 2:

• Continue titrating Seroquel based on response:
  • Day 8: 300 mg
  • Day 9+: Target 300-400 mg/day (therapeutic range for schizophrenia)

This schedule follows the FDA-approved Seroquel titration protocol 1 while allowing overlap to prevent symptom exacerbation.

Key Clinical Considerations

Pharmacological Rationale

Latuda (lurasidone) is a D2 antagonist with high 5-HT2A affinity, while Seroquel (quetiapine) has broader receptor activity including H1, alpha-1, and 5-HT2A receptors with relatively lower D2 affinity. Because you're switching from a D2 partial agonist-like profile to a compound with different pharmacodynamics, the gradual approach is particularly important 2.

Monitoring During the Switch

Critical parameters to assess:

• Psychotic symptoms: Monitor for breakthrough positive symptoms during the overlap period
• Sedation: Quetiapine causes significantly more somnolence (34.7% in bipolar depression studies) compared to lurasidone 3
• Metabolic effects: Quetiapine has higher metabolic burden; baseline and follow-up glucose/lipids are essential
• Orthostatic hypotension: Particularly during the first week due to quetiapine's alpha-1 blockade 1
• Akathisia: Less common with quetiapine than lurasidone (17.7% with lurasidone) 3

Dosing Adjustments

The period of overlapping antipsychotic administration should be minimized 1. If the patient experiences:

• Excessive sedation: Slow the Seroquel titration or give entire dose at bedtime
• Breakthrough psychosis: Maintain higher overlap doses for additional days before continuing taper
• Orthostatic symptoms: Use slower titration (25-50 mg increments every 2-3 days)

Special Populations

Elderly patients: Start Seroquel at 25 mg/day with 25-50 mg/day increments, extending the cross-titration to 2-3 weeks 1.

Hepatic impairment: Begin at 25 mg/day with 25 mg increments 1.

Common Pitfalls to Avoid

1. Abrupt discontinuation of Latuda: While research suggests minimal withdrawal effects 4, clinical practice favors gradual transition to prevent relapse
2. Inadequate Seroquel dosing: The therapeutic range is 300-750 mg/day for schizophrenia; don't stop at 200 mg 1
3. Ignoring metabolic monitoring: Quetiapine requires more intensive metabolic surveillance than lurasidone
4. Overlooking sedation timing: Administering the full dose at bedtime improves tolerability

Reassessment Timeline

Evaluate treatment effectiveness at 4 weeks after reaching therapeutic Seroquel dose 2. If significant symptoms persist with good adherence at therapeutic doses, consider alternative strategies per the 2025 INTEGRATE algorithm, which recommends switching to compounds with different pharmacodynamic profiles after failed trials 2.